Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.55 |
| ▸ | RNASEL | Q05823 | 7/20 | 0.54 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15280847 | 1.00 | ADORA1 (0.55) | ADORA1RNASELP2RY1 | |
| SCHEMBL22060530 | 1.00 | ADORA1 (0.55) | ADORA1RNASELP2RY1 | |
| SCHEMBL15280856 | 0.93 | ADORA1 (0.53) | ADORA1RNASEL | |
| SCHEMBL19887054 | 0.93 | ADORA1 (0.53) | ADORA1RNASEL | |
| SCHEMBL15280780 | 0.92 | ADORA1 (0.51) | ADORA1RNASELP2RY1 | |
| SCHEMBL22060520 | 0.92 | ADORA1 (0.51) | ADORA1RNASELP2RY1 | |
| SCHEMBL19887018 | 0.92 | ADORA1 (0.51) | ADORA1RNASELP2RY1 | |
| SCHEMBL19887071 | 0.91 | RNASEL (0.60) | ADORA1RNASELP2RY1 | |
| SCHEMBL22292292 | 0.91 | RNASEL (0.60) | ADORA1RNASELP2RY1 | |
| SCHEMBL15280878 | 0.91 | RNASEL (0.60) | ADORA1RNASELP2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180051285-A1 | CATIONIC LIPID | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-02-22 | — | — | US | disclosed |
| US-8987226-B2 | Modified single-stranded polynucleotides | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-03-24 | — | — | US | disclosed |
| US-20130253038-A1 | Modified Single-Stranded Polynucleotide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180051285-A1 | CATIONIC LIPID | CETP, NPC1L1, LIPA | ADORA1 986/4885RNASEL 468/4885P2RY1 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.